Policy & Regulation
Serimmune, Mymee Collaborate on Research Study to Better Define the Role of Antibodies in SARS-CoV-2 Symptoms
21 September 2021 - - US-based Serimmune, a specialist in understanding the antibody repertoire's role in human disease, and digital care program provider Mymee will collaborate on a clinical research study to describe the role antibodies play in patients suffering from COVID-19, the companies said.

The partnership includes collaborating on research to understand the presence of antibodies in people with autoimmunity, including disease activity and those most at risk.

The study, which will use Serimmune's proprietary Serum Epitope Repertoire Analysis technology, is designed to assess individual immune responses to SARS-CoV-2 from both natural infection and vaccination, and track those responses over a five-year period.

This data will help researchers better understand how variations in antibody response may influence COVID-19 symptoms from very mild to severe.

More than 200 m COVID cases and 4 m deaths have been reported globally since the pandemic began in December 2019.

Experts predict that up to 35% of both asymptomatic and symptomatic COVID cases will develop some form of long haul COVID.

As part of this collaboration agreement, patients participating in Mymee's digital care programs for autoimmunity and long haul COVID will be eligible to participate.

Participants in the study will receive access to their personalized antibody map, which characterizes their own unique set of antibodies to SARS-CoV-2, and will be provided with ongoing information about their immunity to the virus over time.

Serimmune is in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens.

The company's Serum Epitope Repertoire Analysis technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity.

Serimmune's human immunity map is a growing database that can be interrogated to uncover disease information for the development of multiplex diagnostics, vaccines and therapeutics. The company was founded in 2014 and is backed by investors such as Illumina Ventures, LabCorp, and Merck.

Mymee is the provider of digital care programs designed to help people with autoimmune disease and COVID long haul reclaim their health.

Published research has established that 80% of immune system function is controlled by environmental factors, including diet and lifestyle.

Mymee's platform combines data analytics and one-on-one coaching to find each person's triggers.